Prevail Therapeutics Inc. (NASDAQ:PRVL) headquartered in New York, will host a conference call for the investment community to discuss the 2Q20 financial results on 11th August 2020 at 7:30 AM Eastern Time.
The conference call will also be webcast live under the investor relations section of the website www.prevailtherapeutics.com
Earnings Expectation
Prevail Therapeutics Inc. is expected to report second quarter earnings results, before market open, on Tuesday 11th August 2020. Analysts polled by Thomson Reuters anticipate second quarter loss of $ 0.59 per share. Looking ahead, the full year loss are expected at $ 2.38 per share.
Prevail Therapeutics Inc., a gene therapy company, focuses on developing and commercializing disease-modifying AAV-based gene therapies for patients with devastating neurodegenerative diseases. The companys lead product candidate is PR001 for the treatment of Parkinsons disease with GBA1 mutation and neuronopathic Gaucher disease. It is also developing PR006 for the treatment of frontotemporal dementia with GRN mutation and PR004 for the treatment of synucleinopathies.
